DE3689846D1 - Erhöhte ausscheidung von heterologen proteinen durch wirtszellen durch verwendung von substituierten promotoren. - Google Patents

Erhöhte ausscheidung von heterologen proteinen durch wirtszellen durch verwendung von substituierten promotoren.

Info

Publication number
DE3689846D1
DE3689846D1 DE3689846T DE3689846T DE3689846D1 DE 3689846 D1 DE3689846 D1 DE 3689846D1 DE 3689846 T DE3689846 T DE 3689846T DE 3689846 T DE3689846 T DE 3689846T DE 3689846 D1 DE3689846 D1 DE 3689846D1
Authority
DE
Germany
Prior art keywords
dna
promotors
substituted
host cells
signal sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3689846T
Other languages
English (en)
Other versions
DE3689846T2 (de
Inventor
Joachim Ernst
Ursula Schmeissner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DE3689846D1 publication Critical patent/DE3689846D1/de
Publication of DE3689846T2 publication Critical patent/DE3689846T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Lubricants (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE3689846T 1985-11-25 1986-11-24 Erhöhte ausscheidung von heterologen proteinen durch wirtszellen durch verwendung von substituierten promotoren. Expired - Lifetime DE3689846T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858529014A GB8529014D0 (en) 1985-11-25 1985-11-25 Enhanced secretion of heterologous proteins
PCT/EP1986/000675 WO1987003300A1 (en) 1985-11-25 1986-11-24 Enhanced secretion of heterologous proteins by hosts using substituted promoters

Publications (2)

Publication Number Publication Date
DE3689846D1 true DE3689846D1 (de) 1994-06-23
DE3689846T2 DE3689846T2 (de) 1994-09-22

Family

ID=10588758

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3689846T Expired - Lifetime DE3689846T2 (de) 1985-11-25 1986-11-24 Erhöhte ausscheidung von heterologen proteinen durch wirtszellen durch verwendung von substituierten promotoren.

Country Status (8)

Country Link
US (1) US5082783A (de)
EP (1) EP0283475B1 (de)
JP (2) JP2528849B2 (de)
AT (1) ATE105865T1 (de)
CA (1) CA1318617C (de)
DE (1) DE3689846T2 (de)
GB (1) GB8529014D0 (de)
WO (1) WO1987003300A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281246A3 (de) * 1987-02-04 1989-07-12 Invitron Corporation Verfahren zur Erhöhung der Amplifikation und Expression fremder Gene
US5030563A (en) * 1987-07-07 1991-07-09 Genetics Institute, Inc. Bacterial hypersecretion using mutant repressor sequence
EP1892296A1 (de) * 1988-09-02 2008-02-27 Dyax Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
DE4107612A1 (de) * 1991-03-09 1992-09-10 Behringwerke Ag Rekombinante proteine mit der immunreaktivitaet des hepatitis b virus e antigens (hbeag), verfahren zu ihrer herstellung und ihre verwendung in immunoassays und impfstoffen
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5925564A (en) * 1991-11-06 1999-07-20 Baylor College Of Medicine Expression vector systems and method of use
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
JPH11507205A (ja) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EP0878552A1 (de) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
EP1078098A1 (de) * 1998-05-04 2001-02-28 Dako A/S Verfahren und sonden zur detektion chromosomaler aberrationen
AUPP655698A0 (en) * 1998-10-16 1998-11-05 Commonwealth Scientific And Industrial Research Organisation Delivery system for porcine somatotropin
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
GB0314856D0 (en) * 2003-06-25 2003-07-30 Unitargeting Res As Protein expression system
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
EP2327718B1 (de) 2003-11-21 2016-03-23 Pfenex, Inc. Verbessertes Expressionssystem mit SEC-System-Sekretion
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8067375B2 (en) * 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
RU2559532C2 (ru) 2006-11-02 2015-08-10 Акселерон Фарма, Инк. Антагонисты рецептора и лигандов alk1 и их применение
KR101491867B1 (ko) * 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US20110020830A1 (en) * 2008-03-31 2011-01-27 Schneider Jane C Design for rapidly cloning one or more polypeptide chains into an expression system
CA2723449C (en) 2008-05-02 2020-01-21 Acceleron Pharma Inc. Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
CN108341863A (zh) 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
JP2015506961A (ja) 2012-02-02 2015-03-05 アクセルロン ファーマ， インコーポレイテッド Ａｌｋ１アンタゴニストおよび腎細胞癌の治療におけるその使用
KR20160029731A (ko) 2013-03-12 2016-03-15 더 제너럴 하스피탈 코포레이션 변형된 뮐러관 억제 물질(mis) 단백질 및 질환 치료를 위한 그 용도
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
JP6546587B2 (ja) 2013-10-25 2019-07-17 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． 線維性疾患を処置するためのエンドグリンポリペプチド
EP3079712B1 (de) 2013-12-11 2022-02-02 The General Hospital Corporation Verwendung von anti-müller-hormon (amh)-proteine zur kontrazeption und ovariellen reservekonservierung
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
EP4241848A3 (de) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Fusionsproteine vom tgf-beta-rezeptor typ ii und verwendungen davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411994A (en) * 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
EP0116201B1 (de) * 1983-01-12 1992-04-22 Chiron Corporation Sekretorische Expression in Eukaryoten
DE3486491T2 (de) * 1983-04-25 2003-01-16 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
FR2579224B1 (fr) * 1985-03-25 1987-05-22 Genetica Procede de preparation microbiologique de la serum-albumine humaine

Also Published As

Publication number Publication date
GB8529014D0 (en) 1986-01-02
EP0283475B1 (de) 1994-05-18
US5082783A (en) 1992-01-21
EP0283475A1 (de) 1988-09-28
JP2572952B2 (ja) 1997-01-16
JPH07222595A (ja) 1995-08-22
JPS63502717A (ja) 1988-10-13
JP2528849B2 (ja) 1996-08-28
DE3689846T2 (de) 1994-09-22
CA1318617C (en) 1993-06-01
ATE105865T1 (de) 1994-06-15
WO1987003300A1 (en) 1987-06-04

Similar Documents

Publication Publication Date Title
DE3689846D1 (de) Erhöhte ausscheidung von heterologen proteinen durch wirtszellen durch verwendung von substituierten promotoren.
ATE90966T1 (de) Expression von protein-c.
KR860008285A (ko) 심방의 나트륨 이뇨성/혈관 확장성 폴리펩티드의 제조방법
ES551913A0 (es) Un metodo para obtener expresion de una secuencia de codificacion deseada en celulas de mamifero
IE811463L (en) Interferons
CA2032153A1 (fr) Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
LU90408I2 (fr) Regranex-becaplermin
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
ATE97441T1 (de) Verbesserung der expression und sekretion heterologener proteine in hefe mittels trunkierter sequenzen des alpha-faktor-leaders.
AU6801487A (en) Method of producing a recombinant protein complex having human factor VIII:C activity
DE3688900D1 (de) Expression von protein c.
ATE109830T1 (de) Expression von virusproteinen mit immunologischer aktivität.
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
NO943949L (no) DNA som koder for proteinkomplekser med faktor VIII-C-aktivitet, samt fremstilling derav
DE69132814D1 (de) Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
EP0245949A3 (de) Verfahren zur Anwendung von den BK-Virus-Verstärker enthaltenden eukaryotischen Expressionsvektoren
ES2078243T3 (es) Mejoras en o relativas a la expresion eucariotica.
DE69233155D1 (de) Insulinartigen wachstumsfaktor bindendes protein
EP0232107A3 (de) Derivat des menschlichen Lymphotoxin-Polypeptids
EP0271003A3 (de) Expressionsvektoren
ATE87977T1 (de) Herstellung menschlichen somatomedins c.
RU93004936A (ru) Днк, штаммы, способы получения днк, способы получения полипептидов
RU95101019A (ru) Способ получения фактора некроза опухоли, фактор некроза опухоли, днк, клетка, композиция
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi
JPS642586A (en) Western subtype dna and rna molecule of fsme-virus, polypeptide coded by the molecule and its usage

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US